634 related articles for article (PubMed ID: 17647063)
1. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
2. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
3. [New molecular approaches in dermatofibrosarcoma protuberans].
Kaya G
Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363
[TBL] [Abstract][Full Text] [Related]
4. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
Fattoruso SI; Visca P; Lopez M
Clin Ter; 2008; 159(5):361-7. PubMed ID: 18998038
[TBL] [Abstract][Full Text] [Related]
5. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
McArthur GA
Curr Opin Oncol; 2006 Jul; 18(4):341-6. PubMed ID: 16721128
[TBL] [Abstract][Full Text] [Related]
6. Current treatment options in dermatofibrosarcoma protuberans.
Lemm D; Mügge LO; Mentzel T; Höffken K
J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
8. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
Malhotra B; Schuetze SM
Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
[TBL] [Abstract][Full Text] [Related]
9. [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors].
Bianchini L; Maire G; Pedeutour F;
Bull Cancer; 2007 Feb; 94(2):179-89. PubMed ID: 17337387
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
McArthur G
Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
12. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution.
DuBay D; Cimmino V; Lowe L; Johnson TM; Sondak VK
Cancer; 2004 Mar; 100(5):1008-16. PubMed ID: 14983497
[TBL] [Abstract][Full Text] [Related]
13. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
14. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution.
Bowne WB; Antonescu CR; Leung DH; Katz SC; Hawkins WG; Woodruff JM; Brennan MF; Lewis JJ
Cancer; 2000 Jun; 88(12):2711-20. PubMed ID: 10870053
[TBL] [Abstract][Full Text] [Related]
15. Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P; Debiec-Rychter M
Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
[TBL] [Abstract][Full Text] [Related]
16. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
[TBL] [Abstract][Full Text] [Related]
18. [Dermatofibrosarcoma protuberans].
Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
[TBL] [Abstract][Full Text] [Related]
20. [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
Baars A; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2072-6. PubMed ID: 14606355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
